The primary vocation of SoPharma is to become “Industrial Pharmaceutical Establishment» (PPE).

 

For this, a drug manufacturing plant compliant with European Good Manufacturing Practices (GMP) is under construction in Morocco and will be operational by 2026.

 

This unit will be dedicated in Phase 1 to 3 following therapeutic areas: Central Nervous System, Oncology and Cardiometabolism.